Mabwell Bio Gets China Clinical Trial Approval for Vitiligo Drug

MT Newswires Live14:55

Mabwell (Shanghai) Bioscience's (SHA:688062, HKG:2493) clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.

The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.

Shares of the company rose nearly 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651419002?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651419002","market":"sg","top_or_hot":-1,"title":"Mabwell Bio Gets China Clinical Trial Approval for Vitiligo Drug","media":"MT Newswires Live","content":"<html><body><p> Mabwell (Shanghai) Bioscience's (SHA:688062, HKG:2493) clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.</p><p>The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.</p><p>Shares of the company rose nearly 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell Bio Gets China Clinical Trial Approval for Vitiligo Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell Bio Gets China Clinical Trial Approval for Vitiligo Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-16 14:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mabwell (Shanghai) Bioscience's (SHA:688062, HKG:2493) clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.</p><p>The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.</p><p>Shares of the company rose nearly 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDNA","symbol_name":"iShares Genomics Immunology and Healthcare ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651419002","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651419002","pubTimestamp":1784184942,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mabwell  Bioscience's  clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.Shares of the company rose nearly 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","IDNA":"iShares Genomics Immunology and Healthcare ETF","BK1161":"生物科技","GDOC":"Goldman Sachs Future Health Care Equity ETF","02493":"迈威生物-B","BK0239":"医药制造","HYLG":"GLOBAL X HEALTH CARE COVERED CALL & GROWTH ETF","MEDX":"HORIZON KINETICS MEDICAL ETF"},"translate_title":"Mabwell Bio获得中国白癜风药物临床试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":0.9,"IDNA":0.61,"02493":0.9,"GDOC":0.61,"MEDX":0.61,"HYLG":0.61},"content_text":"Mabwell (Shanghai) Bioscience's (SHA:688062, HKG:2493) clinical trial application for 9MW5211 as treatment of vitiligo has been approved by China's National Medical Products Administration.The approval allows the company to proceed with clinical trials of 9MW5211 for the indication, according to a Wednesday Hong Kong bourse filing.Shares of the company rose nearly 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651419002","isCrawlerRequest":true}